56824-87-4

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-chloro-6-methylquinoline-3-carboxylate is used as a starting material for the synthesis of various complex chemical compounds, particularly in the pharmaceutical industry. Its unique structure and properties make it a valuable precursor for the development of new drugs and therapeutic agents.
Used in Chemical Research:
In the field of chemical research, Ethyl 4-chloro-6-methylquinoline-3-carboxylate is used as a research compound to study the properties and reactions of quinolines and their derivatives. This helps in understanding the reactivity and potential applications of these compounds in various chemical processes.
Used in Organic Synthesis:
Ethyl 4-chloro-6-methylquinoline-3-carboxylate is used as a key intermediate in organic synthesis, particularly for the preparation of other quinolines and their derivatives. Its presence in the molecule allows for further functionalization and modification, leading to the development of new organic compounds with potential applications in various industries.

InChI:InChI=1/C13H12ClNO2/c1-3-17-13(16)10-7-15-11-5-4-8(2)6-9(11)12(10)14/h4-7H,3H2,1-2H3

Upstream product

• 85418-82-2 ethyl 4-hydroxy-6-methylquinoline-3-carboxylate 
• 79607-24-2 6-methyl-4-carbonylquinoline-3-carboxylic acid ethyl ester 
• 19056-84-9 diethyl 2-[(p-tolylamino)methylidene]malonate 
• 106-49-0 p-toluidine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 40516-46-9 diethyl (ethoxymethylene)malonate 

Downstream Products

• 77779-90-9 8-methyl-2-phenyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 774585-94-3 2-(4-fluorophenyl)-8-methyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 774585-95-4 2-(4-bromo-phenyl)-8-methyl-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one 
• 774585-93-2 2-(4-methoxyphenyl)-8-methyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 866143-84-2 6-methyl-2-phenylpyrazolo[4,3-c]quinolin-3-one 
• 774586-00-4 8-methyl-2-(4-bromophenyl)-5-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 774585-97-6 8-methyl-2-(4-methoxyphenyl)-5-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 774585-98-7 8-methyl-2-(4-fluorophenyl)-5-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 774585-99-8 8-methyl-2-(4-chlorophenyl)-5-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 774585-85-2 8-methyl-2-phenyl-5-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one 
• 77779-92-1 2-(4-chloro-phenyl)-8-methyl-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one 

Relevant academic research and scientific papers

Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights

Aurora kinases (AURKs) were identified as promising druggable targets for targeted cancer therapy. Aiming at the development of novel chemotype of dual AURKA/B inhibitors, herein we report the design and synthesis of three series of 4-anilinoquinoline derivatives bearing a sulfonamide moiety (5a-d, 9a-d and 11a-d). The percent inhibition of AURKA/B was determined for all target quinolines, then compounds showed more than 50percent inhibition on either of the enzymes, were evaluated further for their IC50 on the corresponding enzyme. In particular, compound 9d displayed potent AURKA/B inhibitory activities with IC50 of 0.93 and 0.09 μM, respectively. Also, 9d emerged as the most efficient anti-proliferative analogue in the US-NCI anticancer assay toward the NCI 60 cell lines panel, with broad spectrum activity against different cell lines from diverse cancer subpanels. Docking studies, confirmed that, the sulfonamide SO2 oxygen was involved in a hydrogen bond with Lys162 and Lys122 in AURKA and AURKB, respectively, whereas, the sulfonamide NH could catch hydrogen bond interaction with the surrounding amino acid residues Lys141, Glu260, and Asn261 in AURKA and Lys101, Glu177, and Asp234 in AURKB. Furthermore, N1 nitrogen of the quinoline scaffold formed an essential hydrogen bond with the hinge region key amino acids Ala213 and Ala173 in AURKA and AURKB, respectively.

A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease

2-(piperazin-1-yl)–N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as a new class of selective and potent acetylcholinesterase (AChE) inhibitors and amyloid β aggregation inhibitors. Formation of synthesized compounds (P1–P9) was justified via H1 NMR, C13 NMR, mass spectra and single crystal X-Ray diffraction study. All compounds were evaluated for their acetylcholinesterase and butyrylcholinesterase inhibitory activity, inhibition of self-mediated Aβ aggregation and Cu(II)-mediated Aβ aggregation. Also, docking study carried out was in concordance with in vitro results. The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity (IC50 = 4.8 nM). Kinetic study of P3 suggested it to be a mixed type inhibitor. In vitro study revealed that all the compounds are capable of inhibiting self-induced β-amyloid (Aβ) aggregation with the highest inhibition percentage to be 81.65%. Potency of P1 and P3 to inhibit self-induced Aβ1-42 aggregation was ascertained by TEM analysis. Compounds were also evaluated for their Aβ disaggregation, antioxidation, metal-chelation activity.

Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors

Carbonic anhydrases (CAs, EC 4.2.1.1) are crucial metalloenzymes that are involved in diverse bioprocesses. We report the synthesis and biological evaluation of novel series of benzenesulfonamides incorporating un/substituted ethyl quinoline-3-carboxylate moieties. The newly synthesised compounds were in vitro evaluated as inhibitors of the cytosolic human (h) isoforms hCA I and II. Both isoforms hCA I and II were inhibited by the quinolines reported here in variable degrees: hCA I was inhibited with KIs in the range of 0.966–9.091 μM, whereas hCA II in the range of 0.083–3.594 μM. The primary 7-chloro-6-flouro substituted sulphfonamide derivative 6e (KI = 0.083 μM) proved to be the most active quinoline in inhibiting hCA II, whereas, its secondary sulfonamide analog failed to inhibit the hCA II up to 10 μM, confirming the crucial role of the primary sulphfonamide group, as a zinc-binding group for CA inhibitory activity.

Synthesis and pharmacological evaluation of pyrazolo[4,3-c]quinolinones as high affinity GABAA-R ligands and potential anxiolytics

The synthesis, in vitro ligand binding study and in vivo Elevated Plus Maze test (EPM) of a series of pyrazolo[4,3-c]quinolin-3-ones (PQs) are reported. Multistep synthesis of PQs started from anilines and diethyl 2-(ethoxymethylene)malonate to give the q

Tetracyclic lactam compound, preparation method and application thereof

The invention relates to a tetracyclic lactam compound, or a tautomer, a stereisomer, racemate, a non-equivalent mixture of an enantiomer, a geometrical isomer, a solvate, medically acceptable salt orprodrug thereof, and a drug combination containing the same. The invention further discloses application of the tetracyclic lactam compound or the drug combination serving as drugs, particularly as antibacterial, antiviral and antiparasitic drugs.

Lactam-containing tetracyclic derivative as well as preparation method and application thereof

The invention relates to a lactam-containing tetracyclic derivative, or a heterogeneous mixture of a tautomer, a stereoisomer, a raceme and an enantiomer of the lactam-containing tetracyclic derivative, a geometrical isomer, a solvate, medically acceptable salt or a prodrug, and a drug composition containing the compound. The invention further discloses use of the compound and the drug compositionthereof as an insecticide, a bactericide and a herbicide in the agricultural field.

Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors

The serine-threonine checkpoint kinase 1 (Chk1) plays a critical role in the cell cycle arrest in response to DNA damage. In the last decade, Chk1 inhibitors have emerged as a novel therapeutic strategy to potentiate the anti-tumour efficacy of cytotoxic chemotherapeutic agents. In the search for new Chk1 inhibitors, a congeneric series of 2-aryl-2 H-pyrazolo[4,3-c]quinolin-3-one (PQ) was evaluated by in-vitro and in-silico approaches for the first time. A total of 30 PQ structures were synthesised in good to excellent yields using conventional or microwave heating, highlighting that 14 of them are new chemical entities. Noteworthy, in this preliminary study two compounds 4e2 and 4h2 have shown a modest but significant reduction in the basal activity of the Chk1 kinase. Starting from these preliminary results, we have designed the second generation of analogous in this class and further studies are in progress in our laboratories.

Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans

The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of

Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies

In present study a series of triazolopyrimidine-quinoline and cyanopyridine-quinoline hybrids were designed, synthesized and evaluated as acetylcholinesterase inhibitors (AChEIs). Molecular docking and scoring was utilized for the design of inhibitors. The molecules were synthesized via an easily accessible, convergent synthetic route. Three triazolopyrimidine based compounds showed nanomolar activity towards acetylcholinesterase. Among them, Ethyl 6-fluoro-4-(4-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl)quinoline-3-carboxylate (10d), strongly inhibited AChE with IC50 value of 42 nM. Furthermore compound 10d was identified as most promising compound with 12 fold selectivity against butyrylcholinesterase (BuChE). This compound displayed a composed multitargeted profile with promising inhibition of self-induced and AChE - induced Aβ aggregation and antioxidant activity.

Structural evaluation of three 2-phenylpyrazolo[4,3-c]quinolin-3-one monohydrates

A single crystal X-ray diffraction and theoretical study has been carried out on mono hydrates of three 2H-pyrazolo[4,3-c]quinolin-3(5H)-one derivatives, namely 6-methyl-2-phenylpyrazolo[4,3-c]quinolin-3-one, 3, 6-methyl-2-(4- chlorophenyl)pyrazolo[4,3-c]quinolin-3-one, 4, and 8-methyl-2-(4-nitrophenyl) pyrazolo[4,3-c]quinolin-3-one, 5. The monohydrates were obtained on recrystallization from moist solvents. While there are three tautomeric forms possible for such pyrazolo[4,3-c]quinolin-3-one molecules, the sole form isolated in the solid [(X)×(H2O)] (X = 3, 4 and 5) compounds was the quinoloid form - the one calculated to be the most stable at the M06-2X/6-311++G(d,p) level of theory. Excellent agreement was found between the calculated and X-ray determined structures. Molecule 5 in [(5)×(H 2O)] is very near planar while both molecules 3 and 4 in their respective hydrates are much less so as a consequence of angles about 24 between the two aromatic rings. In each hydrate, the pyrazolo[4,3-c]quinolin-3-one molecule is bonded to three water molecules and each water molecule is likewise H-bonded to three pyrazolo[4,3-c]quinolin-3-one molecules. While the water molecules are H-bonded to 3 and 4 via the pyridinyl N and 2x the carbonyl O atoms, in [(5)×(H2O)] the H-bonds are to pyridinyl N, carbonyl O and a nitro O atoms. Calculations indicated that the found arrangement in [(5)×(H2O)] is more stable than one using the connections as found in [(3)×(H2O)] and [(4)×(H2O)]. While each of the hydrates possess strong N-H?O and O-H?O hydrogen bonds, and weaker C-H?π and π?π interactions, the supramolecular arrays are very different.